Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.40 |
| ▸ | DRD4 | P21917 | 7/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 5/20 | 0.33 |
| ▸ | MAOA | P21397 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7769530 | 0.99 | DRD2 (0.39) | DRD2DRD4GPR84PYCR1MAOB | |
| SCHEMBL8892605 | 0.86 | DRD2 (0.40) | DRD2DRD4GPR84TP53CYP1A2 | |
| SCHEMBL6046749 | 0.82 | PYCR1 (0.32) | PYCR1MAOBMAOA | |
| SCHEMBL5953124 | 0.81 | DRD2 (0.40) | DRD2DRD4GPR84MAOBMAOA | |
| SCHEMBL5953729 | 0.80 | DRD2 (0.44) | DRD2DRD4GPR84TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL9056904 | 0.80 | DRD2 (0.40) | DRD2DRD4GPR84MAOBMAOA | |
| SCHEMBL5953495 | 0.79 | TP53 (0.40) | DRD2DRD4GPR84MAOATP53 | |
| SCHEMBL5953253 | 0.79 | KMT2A (0.40) | DRD2DRD4GPR84MAPT | |
| SCHEMBL5953330 | 0.77 | DRD2 (0.40) | DRD2DRD4GPR84LMNA | |
| Hydrochloric Acid SCHEMBL7773505 | 0.76 | DRD2 (0.42) | DRD2DRD4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | claimed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | claimed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | claimed |
| EP-0726265-B1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | NOVARTIS AG (CH) | 2001-07-25 | — | — | EP | claimed |
| EP-1890739-A1 | COMPOSITIONS AND METHODS FOR TREATING DIVERTICULAR DISEASE | ANGIOTECH INTERNATIONAL AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20060286167-A1 | Compositions and methods for the treatment of neurodegenerative diseases | STAUNTON JANE | 2006-12-21 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006124021-A1 | COMPOSITIONS AND METHODS FOR TREATING DIVERTICULAR DISEASE | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006119329-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1691852-A2 | MEDICAL IMPLANTS AND FIBROSIS-INDUCING AGENTS | Angiotech International AG (CH) | 2006-08-23 | — | — | EP | disclosed |
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | disclosed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| US-20050222269-A1 | Use of deprenyl compounds to treat viral infections and reduce tissue damage associated therewith | TATTON WILLIAM G | 2005-10-06 | — | — | US | disclosed |
| WO-2005065079-A2 | MEDICAL IMPLANTS AND FIBROSIS-INDUCING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005046746-A2 | MEDICAL IMPLANTS AND FIBROSIS-INDUCING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | disclosed |
| US-20020137786-A1 | DEPRENYL COMPOUNDS TO TREAT VIRAL INFECTIONS AND REDUCE TISSUE DAMAGE ASSOCIATED THEREWITH | TATTON WILLIAM G (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | DRD2 3652/4885DRD4 2863/4885GPR84 3741/4885 |
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | DBH, MAOB, AADAT | DRD2 28/4885DRD4 79/4885GPR84 209/4885 |
| US-20020137786-A1 | DEPRENYL COMPOUNDS TO TREAT VIRAL INFECTIONS AND REDUCE TISSUE DAMAGE ASSOCIATED THEREWITH | DIMT1, DUT, EIF2AK2 | DRD2 1906/4885DRD4 829/4885GPR84 3564/4885 |
| US-20050222269-A1 | Use of deprenyl compounds to treat viral infections and reduce tissue damage associated therewith | IDO1, DIMT1, DNPEP | DRD2 2098/4885DRD4 1077/4885GPR84 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.